Literature DB >> 19124659

Postantibiotic effects of telavancin against 16 gram-positive organisms.

G A Pankuch1, P C Appelbaum.   

Abstract

The in vitro postantibiotic effects (PAEs), postantibiotic sub-MIC effects (PA-SMEs), and sub-MIC effects of telavancin were determined for 16 gram-positive organisms. Telavancin staphylococcal, streptococcal, and enterococcal PAE ranges were 0.9 to 3.9 h, 0.4 to 6.7 h, and 0.3 to 2.2 h, respectively. The PA-SME ranges (0.4 times the MIC) for staphylococci, streptococci, and enterococci were 6.7 to >10.7 h, >10.7 to >11.0 h, and >10 to >10.8 h, respectively. The extended PAE of telavancin, together with its long elimination half-life in humans, supports once-daily dosing for this investigational drug.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19124659      PMCID: PMC2650569          DOI: 10.1128/AAC.01244-08

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  15 in total

1.  Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects.

Authors:  J P Shaw; J Seroogy; K Kaniga; D L Higgins; M Kitt; S Barriere
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

2.  Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus.

Authors:  Deborah L Higgins; Ray Chang; Dmitri V Debabov; Joey Leung; Terry Wu; Kevin M Krause; Erik Sandvik; Jeffrey M Hubbard; Koné Kaniga; Donald E Schmidt; Qiufeng Gao; Robert T Cass; Dane E Karr; Bret M Benton; Patrick P Humphrey
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

Review 3.  The post-antibiotic sub-MIC effect in vitro and in vivo.

Authors:  O Cars; I Odenholt-Tornqvist
Journal:  J Antimicrob Chemother       Date:  1993-05       Impact factor: 5.790

4.  Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria.

Authors:  Martin E Stryjewski; William D O'Riordan; William K Lau; Francis D Pien; Lala M Dunbar; Marc Vallee; Vance G Fowler; Vivian H Chu; Elizabeth Spencer; Steven L Barriere; Michael M Kitt; Christopher H Cabell; G Ralph Corey
Journal:  Clin Infect Dis       Date:  2005-04-28       Impact factor: 9.079

5.  Studies on the postantibiotic effect and the postantibiotic sub-MIC effect of meropenem.

Authors:  I Odenholt-Tornqvist
Journal:  J Antimicrob Chemother       Date:  1993-06       Impact factor: 5.790

6.  In vitro activity of TD-6424 against Staphylococcus aureus.

Authors:  John L Pace; Kevin Krause; Deborah Johnston; Dmitri Debabov; Terry Wu; Lesley Farrington; Cassie Lane; Deborah L Higgins; Burt Christensen; J Kevin Judice; Koné Kaniga
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

7.  Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study.

Authors:  Martin E Stryjewski; Vivian H Chu; William D O'Riordan; Brian L Warren; Lala M Dunbar; David M Young; Marc Vallée; Vance G Fowler; Joel Morganroth; Steven L Barriere; Michael M Kitt; G Ralph Corey
Journal:  Antimicrob Agents Chemother       Date:  2006-03       Impact factor: 5.191

Review 8.  Pharmacodynamics of antimicrobial agents as a basis for determining dosage regimens.

Authors:  W Craig
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993       Impact factor: 3.267

9.  Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.

Authors:  Deborah C Draghi; Bret M Benton; Kevin M Krause; Clyde Thornsberry; Chris Pillar; Daniel F Sahm
Journal:  Antimicrob Agents Chemother       Date:  2008-04-28       Impact factor: 5.191

10.  In vitro studies of pharmacodynamic properties of vancomycin against Staphylococcus aureus and Staphylococcus epidermidis.

Authors:  E Löwdin; I Odenholt; O Cars
Journal:  Antimicrob Agents Chemother       Date:  1998-10       Impact factor: 5.191

View more
  9 in total

1.  In vitro activity of telavancin in combination with colistin versus Gram-negative bacterial pathogens.

Authors:  Michael Hornsey; Christopher Longshaw; Lynette Phee; David W Wareham
Journal:  Antimicrob Agents Chemother       Date:  2012-04-09       Impact factor: 5.191

2.  Pharmacodynamics of telavancin studied in an in vitro pharmacokinetic model of infection.

Authors:  Alasdair P MacGowan; Alan R Noel; Sharon Tomaselli; Heather C Elliott; Karen E Bowker
Journal:  Antimicrob Agents Chemother       Date:  2010-11-15       Impact factor: 5.191

Review 3.  Telavancin: a novel semisynthetic lipoglycopeptide agent to counter the challenge of resistant Gram-positive pathogens.

Authors:  Biswadeep Das; Chayna Sarkar; Debasmita Das; Amit Gupta; Arnav Kalra; Shubham Sahni
Journal:  Ther Adv Infect Dis       Date:  2017-03-08

4.  Successful target attainment of telavancin at elevated MICs: fact or fiction?

Authors:  Andras Farkas
Journal:  Antimicrob Agents Chemother       Date:  2012-08       Impact factor: 5.191

Review 5.  New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin.

Authors:  George G Zhanel; Divna Calic; Frank Schweizer; Sheryl Zelenitsky; Heather Adam; Philippe R S Lagacé-Wiens; Ethan Rubinstein; Alfred S Gin; Daryl J Hoban; James A Karlowsky
Journal:  Drugs       Date:  2010-05-07       Impact factor: 9.546

6.  Telavancin.

Authors:  Katherine A Lyseng-Williamson; Stephanie K A Blick
Journal:  Drugs       Date:  2009       Impact factor: 9.546

Review 7.  Telavancin: a review of its use in patients with nosocomial pneumonia.

Authors:  Lesley J Scott
Journal:  Drugs       Date:  2013-11       Impact factor: 9.546

8.  Telavancin: A novel lipoglycopeptide antibiotic.

Authors:  S E Damodaran; S Madhan
Journal:  J Pharmacol Pharmacother       Date:  2011-04

9.  Telavancin for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA).

Authors:  Candace Y Hooper; Winter J Smith
Journal:  Ther Clin Risk Manag       Date:  2012-03-16       Impact factor: 2.423

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.